1.
Ferroptosis as a potential therapeutic target in various cancers
| Cancer type | Drug | Pathway (targets) | Ferroptosis component | Reference |
| Breast cancer | Tamoxifen | Transferrin receptor | Iron metabolism | 59 |
| Breast cancer | Faslodex | Transferrin receptor | Iron metabolism | 59 |
| Breast cancer | Artemisinin | Transferrin | Iron metabolism | 83 |
| Breast cancer | Doxorubicin | Ferritin | Iron metabolism | 64 |
| Breast cancer | Doxorubicin | Ferritin | Iron metabolism | 63 |
| Breast cancer | Cisplatin | Ferritin | Iron metabolism | 63 |
| Breast cancer | Siramesine and Lapatinib | Ferritin | Iron metabolism | 61 |
| Breast cancer | Ironomycin/AM5 | Ferritin | Iron metabolism | 84 |
| Breast cancer | Doxorubicin | Ferroportin-1 | Iron metabolism | 85 |
| Breast cancer | Siramesine and Lapatinib | Ferroportin-1 | Iron metabolism | 55 |
| Breast cancer | Etoposide | Iron chelator | Iron metabolism | 86 |
| Erythroleukemia | Doxorubicin | Transferrin | Iron metabolism | 87 |
| Promyelocytic leukemia | Doxorubicin | Transferrin | Iron metabolism | 86 |
| Leukemia | Doxorubicin | Transferrin receptor | Iron metabolism | 58 |
| Leukemia | Artemisinin | Transferrin receptor | Iron metabolism | 57 |
| Leukemia | Artemisinin | Transferrin receptor | Iron metabolism | 88 |
| Myeloma | Bortezomib | Ferritin | Iron metabolism | 62 |
| Ovarian cancer | Platinum | Ferroportin-1, transferrin receptor | Iron metabolism | 65 |
| Small-cell lung cancer | Artemisinin | Transferrin | Iron metabolism | 60 |
| Epidermoid carcinoma | Vinblastine | Iron chelator | Iron metabolism | 85 |
| Glioma | Carmustine | H-ferritin | Iron metabolism | 89 |
| Glioma | Temozolomide | System Xc- | System Xc- | 90 |
| Glioma | Sulfasalazine | System Xc- | System Xc- | 90 |
| Glioma | Temozolomide | AFT4--System Xc- | System Xc- | 71 |
| Glioma | Pseudolaric acid B | p53--System Xc- | System Xc- | 73 |
| Melanoma | Vemurafenib | System Xc- | System Xc- | 68 |
| Head and neck cancer | Cisplatin | System Xc- | System Xc- | 66 |
| Hepatocellular carcinoma | Sorafenib | System Xc- | System Xc- | 91 |
| Pancreatic cancer | Gemcitabine | System Xc- | System Xc- | 41 |
| Head and neck cancer | Dihydroartemisinin | GPX4† | Lipid ROS and antioxidants | 92 |
| Head and neck cancer | Sulfasalazine | Lipid ROS | Lipid ROS and antioxidants | 93 |
| Hepatocellular carcinoma | Sorafenib | Lipid ROS | Lipid ROS and antioxidants | 94 |
| Pancreatic cancer | Gemcitabine | Lipid ROS | Lipid ROS and antioxidants | 95 |
| Rhabdomyosarcoma | Doxorubicin | GSH‡ | Lipid ROS and antioxidants | 96 |
| Small-cell lung cancer | Cisplatin | GSH‡ | Lipid ROS and antioxidants | 97 |
| Head and neck cancer | Artesunate | NRF2-ARE§ pathway | NRF2 pathway | 77 |
| Head and neck cancer | Cisplatin | NRF2-ARE§ pathway | NRF2 pathway | 78 |
| Hepatocellular carcinoma | Sorafenib | p62-Keap1-NRF2 pathway | NRF2 pathway | 76 |
| Ovarian cancer | Cisplatin | Unknown | Others | 67 |
| Head and neck cancer | Sulfasalazine | ALDHs¶ | Others | 98 |
| † GXP4: glutathione peroxidase 4; ‡ GSH: glutathione; § NRF2-ARE: nuclear factor (erythroid-derived 2) like 2 - antioxidant response element; ¶ ALDHs: aldehyde dehydrogenases. | ||||